GlaxoSmithKline UK

Stockley Park West, Uxbridge, Middlesex, UB11 1BT
Telephone: +44 (0)800 221 441
Fax: +44 (0)208 990 4328
Medical Information e-mail: customercontactuk@gsk.com

Patient Information Leaflet last updated on the eMC: 09/02/2012
PIL Ambirix suspension for injection

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 09/02/2012 and displayed until Current
Reasons for adding or updating:
  • Change to date of revision
  • Change to side-effects
Updated on 16/01/2012 and displayed until 09/02/2012
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
Updated on 02/06/2011 and displayed until 16/01/2012
Reasons for adding or updating:
  • Improved Electronic Presentation
  • Change to date of revision
  • Removal of Black Triangle
Updated on 14/12/2010 and displayed until 02/06/2011
Reasons for adding or updating:
  • Change to date of revision
  • Correction of spelling/typing errors
Updated on 31/03/2009 and displayed until 14/12/2010
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 17/02/2009 and displayed until 31/03/2009
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 30/01/2009 and displayed until 17/02/2009
Reasons for adding or updating:
  • Change to warnings or special precautions for use
Updated on 30/01/2009 and displayed until 30/01/2009
Reasons for adding or updating:
  • Change to warnings or special precautions for use
Updated on 23/04/2008 and displayed until 30/01/2009
Reasons for adding or updating:
  • Transfer to upgraded management system
Updated on 29/02/2008 and displayed until 23/04/2008
Reasons for adding or updating:
  • Change to date of revision
Updated on 11/01/2008 and displayed until 29/02/2008
Reasons for adding or updating:
  • New PIL for new product